BACKGROUND: This study aimed to evaluate HIV type-1 (HIV-1) drug resistance pretreatment and in those failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in South Africa. METHODS: This was an observational cohort. Genotypic resistance testing was performed on treatment-naive individuals and those failing first-line ART (confirmed HIV-1 RNA>1,000 copies/ml) from public sector clinics in Cape Town (2002-2007). Resistance profiles and mutations relative to timing of known virological failure were examined. RESULTS: In total, 230 patients (120 treatment-naive and 110 with virological failure) were included: 98% had clade C virus. Among treatment-naive patients, prevalence of primary resistance was 2.5% (95% confidence interval 0.0-5.3). Three patients had one significant reverse transcriptase mutation: K65R, Y181C and G190A. Among treatment-experienced patients, 95 (86%) individuals had therapy-limiting NNRTI mutations, including K103N (55%), V106M (31%) and Y181C (9%). The M184V mutation was the most common mutation, found in 86 (78%) patients. In total, 10 (9%) patients had the K65R mutation. More individuals tended to develop thymidine analogue mutations when sampling occurred after 6 months of detected therapy failure (10/31 [32%] individuals) compared with those who had genotyping before 6 months (15/79 [19%] patients; P=0.246). CONCLUSIONS: Prevalence of primary resistance in a sample of ART-naive clade C HIV-1-infected individuals in South Africa was low during the study period. Patients failing first-line ART most often developed resistance to NNRTIs and nucleoside reverse transcriptase inhibitors, the two drug classes used in first-line therapy. Viral load monitoring in this setting is crucial and individual genotypes in those failing first-line therapy should be considered.
BACKGROUND: This study aimed to evaluate HIV type-1 (HIV-1) drug resistance pretreatment and in those failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in South Africa. METHODS: This was an observational cohort. Genotypic resistance testing was performed on treatment-naive individuals and those failing first-line ART (confirmed HIV-1 RNA>1,000 copies/ml) from public sector clinics in Cape Town (2002-2007). Resistance profiles and mutations relative to timing of known virological failure were examined. RESULTS: In total, 230 patients (120 treatment-naive and 110 with virological failure) were included: 98% had clade C virus. Among treatment-naive patients, prevalence of primary resistance was 2.5% (95% confidence interval 0.0-5.3). Three patients had one significant reverse transcriptase mutation: K65R, Y181C and G190A. Among treatment-experienced patients, 95 (86%) individuals had therapy-limiting NNRTI mutations, including K103N (55%), V106M (31%) and Y181C (9%). The M184V mutation was the most common mutation, found in 86 (78%) patients. In total, 10 (9%) patients had the K65R mutation. More individuals tended to develop thymidine analogue mutations when sampling occurred after 6 months of detected therapy failure (10/31 [32%] individuals) compared with those who had genotyping before 6 months (15/79 [19%] patients; P=0.246). CONCLUSIONS: Prevalence of primary resistance in a sample of ART-naive clade C HIV-1-infected individuals in South Africa was low during the study period. Patients failing first-line ART most often developed resistance to NNRTIs and nucleoside reverse transcriptase inhibitors, the two drug classes used in first-line therapy. Viral load monitoring in this setting is crucial and individual genotypes in those failing first-line therapy should be considered.
Authors: Rami Kantor; Lynn S Zijenah; Robert W Shafer; Solomon Mutetwa; Elizabeth Johnston; Robert Lloyd; Andrea von Lieven; Dennis Israelski; David A Katzenstein Journal: AIDS Res Hum Retroviruses Date: 2002-12-10 Impact factor: 2.205
Authors: Ana Barroso Abecasis; Koen Deforche; Joke Snoeck; Lee T Bacheler; Paula McKenna; Ana Patrícia Carvalho; Perpétua Gomes; Ricardo Jorge Camacho; Anne-Mieke Vandamme Journal: AIDS Date: 2005-11-04 Impact factor: 4.177
Authors: Bluma G Brenner; Maureen Oliveira; Florence Doualla-Bell; Daniela D Moisi; Michel Ntemgwa; Fernando Frankel; Max Essex; Mark A Wainberg Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Sarah B Lorenzana; Michael D Hughes; Beatriz Grinsztejn; Ann C Collier; Paula Mendes Luz; Kenneth A Freedberg; Robin Wood; Julie H Levison; Peter N Mugyenyi; Robert Salata; Carole L Wallis; Milton C Weinstein; Robert T Schooley; Rochelle P Walensky Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Ziad El-Khatib; Allison K Delong; David Katzenstein; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Max Petzold; Lynn Morris; Rami Kantor Journal: J AIDS Clin Res Date: 2011-02-18
Authors: Thomas A Toni; Bluma G Brenner; Eugene L Asahchop; Michel Ntemgwa; Daniella Moisi; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2009-12-07 Impact factor: 5.191
Authors: Christopher J Hoffmann; Silvia Cohn; Fildah Mashabela; Jennifer D Hoffmann; Helen McIlleron; Paolo Denti; David W Haas; Kelly E Dooley; Neil A Martinson; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731